You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四川雙馬(000935.SZ):控股子公司深圳健元獲得歐洲發明專利
格隆匯 02-16 17:11

格隆匯2月16日丨四川雙馬(000935.SZ)公佈,公司控股子公司深圳市健元醫藥科技有限公司於近期收到了歐洲專利局頒發的發明專利證書。

1 、專利名稱 : SYNTHESIS METHOD FOR LOW‑RACEMIZATION IMPURITY LIRAGLUTIDE(低消旋雜質利拉魯肽的合成方法)

2、專利權人:深圳市健元醫藥科技有限公司

3、專利號:EP35055334、專利類型:發明專利

5、申請日期:2017 年 8 月 18 日

6、授權日期:2025 年 1 月 15 日

利拉魯肽是人胰高血糖素樣肽-1(GLP-1)類似物,用於治療Ⅱ型糖尿病、體重管理。本專利為合成利拉魯肽的新工藝,該工藝在確保收率穩定的同時,實現了與產品性質極為相似的消旋雜質[D‑Thr5 ]-利拉魯肽的大幅降低,有利於提升產品的質量。

歐洲是公司重要的海外市場之一,本次歐洲專利的取得是公司研發綜合實力的體現,將進一步鞏固公司的技術優勢,有助於公司核心競爭力的提升及海外市場的拓展,對公司未來發展和經營活動有積極影響,有利於進一步發揮公司的自主知識產權優勢,維護並加強公司產品在全球市場的競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account